Haematologica (Aug 2018)

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

  • Marek Trnĕný,
  • Gregor Verhoef,
  • Martin JS Dyer,
  • Dina Ben Yehuda,
  • Caterina Patti,
  • Miguel Canales,
  • Andrés Lopez,
  • Farrukh T Awan,
  • Paul G Montgomery,
  • Andrea Janikova,
  • Anna M Barbui,
  • Kazimierz Sulek,
  • Maria J Terol,
  • John Radford,
  • Anna Guidetti,
  • Massimo Di Nicola,
  • Laure Siraudin,
  • Laurence Hatteville,
  • Sandrine Schwab,
  • Corina Oprea,
  • Alessandro M Gianni

DOI
https://doi.org/10.3324/haematol.2017.168401
Journal volume & issue
Vol. 103, no. 8

Abstract

Read online

This phase II, single-arm, multicenter study examined the efficacy and safety of coltuximab ravtansine (an anti-CD19 antibody drug conjugate) in 61 patients with histologically documented (de novo or transformed) relapsed or refractory diffuse large B-cell lymphoma who had previously received rituximab-containing immuno-chemotherapy. Patients had received a median of 2.0 (range 0-9) prior treatment regimens for diffuse large B-cell lymphoma and almost half (45.9%) had bulky disease (≥1 lesion >5 cm) at trial entry. Patients received coltuximab ravtansine (55 mg/m2) in 4 weekly and 4 biweekly administrations until disease progression or unacceptable toxicity. Forty-one patients were eligible for inclusion in the per protocol population. Overall response rate (International Working Group criteria) in the per protocol population, the primary end point, was 18/41 [43.9%; 90% confidence interval (CI:) 30.6-57.9%]. Median duration of response, progression-free survival, and overall survival (all treated patients) were 4.7 (range 0.0-8.8) months, 4.4 (90%CI: 3.02-5.78) months, and 9.2 (90%CI: 6.57-12.09) months, respectively. Common non-hematologic adverse events included asthenia/fatigue (30%), nausea (23%), and diarrhea (20%). Grade 3-4 adverse events were reported in 23 patients (38%), the most frequent being hepatotoxicity (3%) and abdominal pain (3%). Eye disorders occurred in 15 patients (25%); all were grade 1-2 and none required a dose modification. Coltuximab ravtansine monotherapy was well tolerated and resulted in moderate clinical responses in pre-treated patients with relapsed/refractory diffuse large B-cell lymphoma. (Registered at: clinicaltrials.gov identifier: 01472887)